Baxter International (BAX)
27.84
-0.30 (-1.07%)
NYSE · Last Trade: Apr 12th, 12:30 PM EDT
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · April 11, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
Via Chartmill · April 9, 2025
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.
Via Chartmill · April 9, 2025
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Via Chartmill · April 2, 2025

Via Benzinga · February 26, 2025
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Via Chartmill · March 17, 2025

Over the past six months, Baxter’s stock price fell to $36.42. Shareholders have lost 7.3% of their capital, which is disappointing considering the S&P 500 has climbed by 1.5%. This might have investors contemplating their next move.
Via StockStory · March 11, 2025

Via Benzinga · March 10, 2025

Medical device company CooperCompanies (NASDAQ:COO)
will be reporting results tomorrow after market close. Here’s what you need to know.
Via StockStory · March 5, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSE:SYK).
Via StockStory · February 28, 2025

Healthcare is the top-performing sector in the market, up 7.31% and outperforming the S&P 500 by 4.2x. Looks like the rumors of its death were indeed GREATLY EXAGGERATED.
Via Talk Markets · February 27, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSE:BAX).
Via StockStory · February 25, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · February 24, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers.
Via StockStory · February 24, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · February 20, 2025

Healthcare company Baxter International (NYSE:BAX) beat Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $2.75 billion. On the other hand, next quarter’s revenue guidance of $2.58 billion was less impressive, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was significantly above analysts’ consensus estimates.
Via StockStory · February 20, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · February 20, 2025

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via Chartmill · February 20, 2025

Baxter International exceeded Q4 earnings and revenue estimates, with strong pharmaceutical sales. The company issued a mixed 2025 outlook amid cost pressures.
Via Benzinga · February 20, 2025

Healthcare company Baxter International (NYSE:BAX)
will be reporting earnings tomorrow morning. Here’s what investors should know.
Via StockStory · February 19, 2025

Healthcare company Baxter International (NYSE:BAX)
will be announcing earnings results tomorrow morning. Here’s what investors should know.
Via StockStory · February 12, 2025

Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.
Via Benzinga · February 7, 2025